CA-IMAGO-BIOSCIENCES
Imago BioSciences, Inc . (“Imago”), a private clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the European Medicines Agency (EMA) granted access to its PRIME (PRIority MEdicines) scheme for IMG-7289 (bomedemstat), a lysine-specific demethylase-1 (LSD1) inhibitor, for the treatment of intermediate-2 and high-risk patients with myelofibrosis who have become intolerant of, resistant to, or are ineligible for a Janus Kinase (JAK) inhibitor. IMG-7289 is being evaluated in an open-label Phase 2 clinical trial (www.myelofibrosisclinicalstudy.com ) for the treatment of advanced myelofibrosis, a bone marrow cancer that interferes with the production of blood cells.
The PRIME initiative was launched by the EMA in 2016 to provide proactive and enhanced support to the developers of promising medicines with the view of accelerating their evaluation to reach patients faster. To be eligible for PRIME, a medicine must address an unmet medical need and show potential clinical benefit based on early trial data. Myelofibrosis is a progressive cancer in which bone marrow is gradually replaced by fibrous, scar-like tissue impairing the production of blood cells for which treatment options are limited.
"We are excited to receive PRIME designation for IMG-7289, our first LSD1 inhibitor in the clinic,” said Hugh Young Rienhoff, Jr., M.D., CEO of Imago BioSciences. “We intend to work closely with the EMA to optimize our development plans and help bring IMG-7289 to patients as quickly as possible. Myelofibrosis remains a major unmet medical need and IMG-7289 represents a potential new option for patients who don’t benefit from the current standard of care.”
The EMA reviewed IMG-7289 non-clinical and clinical data from the ongoing Phase 2 study, which demonstrated improvements in symptom scores, spleen volumes, anemia and bone marrow fibrosis. Data presented at the 25th European Hematology Association (EHA) Annual Congress demonstrated that IMG-7289 was well tolerated with no dose-limiting toxicities or safety signals. The Phase 2b study is actively enrolling in the U.S., U.K., and E.U.
About IMG-7289 (Bomedemstat)
IMG-7289 is a small molecule invented and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be essential for maturation of blood cells and vital to neoplastic stem/progenitor bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy as a single agent and in combination with other chemotherapeutic agents across a range of myeloid malignancies including leukemia and myeloproliferative neoplasms such as myelofibrosis. IMG-7289 is an investigational agent currently being evaluated in several ongoing clinical trials (ClinicalTrials.gov Identifier: NCT03136185 , NCT04254978 , NCT04262141 , NCT04081220 ). IMG-7289 has FDA Orphan Drug and Fast Track Designation for both the treatment of myelofibrosis and essential thrombocythemia, and Orphan Drug Designation for treatment of acute myeloid leukemia.
About Imago BioSciences
Imago BioSciences is a private clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes. Imago has developed a series of compounds that alter the activity and function of LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell maturation and function. Imago is advancing the clinical development of its first LSD1 inhibitor, IMG-7289, for the treatment of myeloid neoplasms including myelofibrosis, essential thrombocythemia and polycythemia vera. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com and follow us on Twitter @ImagoBioRx , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005280/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Greenland Resources Signs MOU With German GMH Gruppe for Molybdenum Supply20.1.2026 04:19:00 CET | Press release
Greenland Resources Inc. (TSX:MOLY, FSE:M0LY) (“Greenland Resources” or the “Company”) is pleased to announce that as a follow up to its December 3, 2025 press release where the European Commission presented RESourceEU, and mentioned the Company’s Malmbjerg project in Greenland as a priority EU project, the Company has signed a memorandum of understanding (“MOU”) for long term molybdenum supply with GMH Gruppe SE & Co. KG, (GMH), a leading European producer and processor of steel long products, special bar quality, tool steels, forgings and castings. GMH is a pioneer in sustainable steel production using electric arc furnaces based on scrap recycling thus generating 80 percent fewer CO2 emissions than conventionally produced steel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119648070/en/ The MOU sets the path for a long-term supply agreement covering ferro-molybdenum, molybdenum-oxide and briquettes produced from moly
Doha Debates Reflects on a Landmark Year of Global Dialogue and Youth Engagement19.1.2026 17:02:00 CET | Press release
In 2026, Doha Debates addresses the world’s most pressing questions through global dialogue that engages diverse audiences, including youth In 2025, Qatar Foundation’s Doha Debates strengthened its role as a global platform for truth-seeking dialogue, bringing students and leading thinkers together to explore ideas shaping today’s most urgent questions––from freedom and justice to identity and belonging. Its reach continued to grow, surpassing 13.8 million video views and engaging nearly seven million followers across social platforms, including more than one million YouTube subscribers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119796451/en/ In 2026, Doha Debates addresses the world’s most pressing questions through global dialogue that engages diverse audiences, including youth. (Photo: AETOSWire) A major milestone came with season four of The Negotiators, which earned international recognition, winning the Folio A
Evernote Releases v11, Marking a New Chapter in AI-Powered Productivity19.1.2026 17:00:00 CET | Press release
Evernote today announced the release of v11, its first major product update in five years. The new version includes three powerful AI features—AI Assistant, Semantic Search, and AI Meeting Notes—creating smarter ways to capture, retrieve, and manage information in Evernote. With the release of v11, these features are now available to all Evernote customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119103272/en/ Two years of work culminating in a major update V11 is a recognition of Evernote’s evolution under Bending Spoons’ stewardship. Since 2024, Evernote has released more than 250 new features and improvements while also greatly enhancing sync, speed, and reliability. With v11, Evernote ushers in an exciting new phase of development and innovation, bringing customers novel ways to engage with their preferred productivity tool. “Evernote has been part of people’s lives for years, often decades. They’ve always insp
Esmark Expands Global Sports Commitment With Sponsorship of Slovakian Professional Hockey Team19.1.2026 14:00:00 CET | Press release
Sponsorship unites local talent and gives the people of Košice a team of their own Esmark Sports Management and Entertainment, a wholly owned subsidiary of Esmark Inc., announced today it is the team sponsor and co-owner of a newly established professional hockey team in Košice, Slovakia. This partnership underscores Esmark’s commitment to supporting sports development and strengthening community connections through the unifying power of athletics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119104207/en/ Esmark Sports Management and Entertainment, a wholly owned subsidiary of Esmark Inc., is the team sponsor and co-owner of a newly established professional hockey team in Košice, Slovakia. The Hockey Club Esmark Košice team began competing in the 2HL division of professional ice hockey in Slovakia in the 2025-2026 season. The roster features players from Košice who have been competing for clubs across Slovakia. “The cr
WHOOP Becomes Official Health and Fitness Wearable Partner and Team Partner of Scuderia Ferrari HP19.1.2026 13:38:00 CET | Press release
A First in Formula 1: WHOOP to Deliver Health Insights Across the Scuderia Ferrari HP Team WHOOP, the human performance company, today announced a new, global partnership with Scuderia Ferrari HP as the Official Health and Fitness Wearable Partner and Team Partner. Starting in the 2026 season, Scuderia Ferrari HP cars and drivers will host the WHOOP logo, while WHOOP will be provided to members of the team to unlock insights on their health, recovery, and fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119602892/en/ This partnership also unlocks a first-of-its-kind integration in which the medical team supporting Scuderia Ferrari HP will work closely with the WHOOP Performance Science team, led by Dr. Kristen Holmes, on enhancing the physical efficiency and recovery for the entire Scuderia Ferrari HP organization. Together, they will work on the foundational elements of health and fitness with a unique human optim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom